New Drugs on the Block: Dietary Management and Nutritional Considerations During the Use of Anti-Obesity Medication - PubMed
3 hours ago
- #gastrointestinal adverse events
- #anti-obesity medication
- #nutritional management
- Incretin-based pharmacotherapy (e.g., GLP-1 RAs, dual GIP/GLP-1 RAs) is effective for obesity but often causes gastrointestinal (GI) adverse events (AEs) like nausea, vomiting, reflux, diarrhea, and constipation.
- These GI symptoms reduce quality of life, lead to treatment discontinuation, and limit real-world effectiveness due to poor adherence.
- Current clinical trials typically provide general lifestyle advice and hypocaloric diets, lacking structured, mechanism-based nutritional counseling tailored to these drugs.
- Targeted nutritional strategies may mitigate GI AEs, improve tolerability, and support sustained treatment adherence.
- This review synthesizes evidence on GI AEs, proposes structured nutritional management to reduce symptom burden, and offers monitoring strategies for clinicians and dietitians.
- The goal is to bridge pharmacology and clinical nutrition, optimizing patient outcomes and translating trial efficacy into durable real-world success.